Last-Resort cell therapy offered to sarcoma patients
NCT ID NCT06617572
First seen Feb 09, 2026
Summary
This expanded access program offers a cell therapy called afamitresgene autoleucel (afami-cel) to people with synovial sarcoma or myxoid liposarcoma whose manufactured dose didn't meet commercial standards. Eligible patients have no other feasible treatment options. The therapy is given as a single intravenous infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
AVAILABLEBoston, Massachusetts, 02215, United States
Contact
-
Fox Chase Cancer Center
AVAILABLEPhiladelphia, Pennsylvania, 19111, United States
Contact
-
MD Anderson Cancer Center
AVAILABLEHouston, Texas, 77030, United States
Contact
-
Massachusetts General Hospital
AVAILABLEBoston, Massachusetts, 02144, United States
Contact
-
Mayo Arizona
AVAILABLEPhoenix, Arizona, 85259, United States
Contact
-
Mayo Florida
AVAILABLEJacksonville, Florida, 32224, United States
Contact
-
Mayo Rochester
AVAILABLERochester, Minnesota, 55905, United States
Contact
-
Memorial Sloan Kettering Cancer Centre
AVAILABLENew York, New York, 10065, United States
Contact
-
Moffit Cancer Center
AVAILABLETampa, Florida, 33612, United States
Contact
-
Northwestern University Feinberg School of Medicine
AVAILABLEChicago, Illinois, 60601, United States
Contact
-
Stanford Hospital and Clinics
AVAILABLEStanford, California, 94305, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
afamitresgene autoleucel (afami-cel), a cell therapy made from the patient's own immune cells
What this could lead to
If this works, it could provide a treatment option for patients with synovial sarcoma or myxoid liposarcoma who have no other alternatives.
What could go wrong
This is an expanded access program, not a formal trial, so data on effectiveness and safety is limited. The product does not meet commercial specifications, meaning its quality or potency may be lower than standard.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.